I agree. Fauci and the NIH have decided it is unlikely one drug will solve coronavirus. Their decision to proceed with Remdesivir in multiple combination trials isn't because its a great treatment, its is a sign of pressure to produce a treatment as soon as possible and the fact they do not see other treatments emerging as a primary treatment.
This could be good news for Brilacidin if it aces the next RBL human respiratory epithelial cell test. We could be timing this just right to get in a combo trial with Remdesivir and start a single drug trial.
Market Data 
Markets 
AI
